ClinicalTrials.gg
CompletedNCT01392573DUAL™ IIUpdated Jan 3, 2019Results posted

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

A Phase 3 interventional study of insulin degludec/liraglutide and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 86 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-03.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
33rd of 70
413 · median 384
Started
2011
with 7 others
Phase 3
49 of 70
2 open now
Registered
24th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 33rd largest by enrollment, is one of 8 that started in 2011, is one of 49 in phase 3, and was the 24th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with type 2 diabetes. Subjects continue their pre-trial treatment with metformin throughout the entire trial.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 413 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with type 2 diabetes
  • (glycosylated ) 7.5-10.0% (both inclusive)
  • Subjects on stable daily doses for at least 90 days prior to trial start of: Basal insulin (total daily basal insulin dose within the range of 20-40U in combination with: metformin (1500 mg or more or max. tolerated dose) or metformin (1500 mg or more or max. tolerated dose) and SU (sulfonylurea) (equal to or more than half of the max. approved dose according to local label) or metformin and glinides (equal to or more than half of the max. approved dose according to local label)
  • (Body Mass Index) more than or equal to 27 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Treatment with glucagon like peptide-1 (GLP-1) receptor agonists (e.g. exenatide, liraglutide), dipeptidyl peptidase 4 (DPP-4) inhibitors and/or thiazolidinediones within 90 days prior to trial start
  • Impaired liver function
  • Impaired renal function
  • Screening calcitonin equal to or above 50 ng/l
  • Subjects with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
  • Cardiac disorder defined as: congestive heart failure ( class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the last 52 weeks prior to trial start and/or planned coronary, carotid or peripheral artery revascularisation procedures
  • Severe uncontrolled treated or untreated hypertension (systolic blood pressure equal to or above 180 mm Hg or diastolic blood pressure equal to or above 100 mm Hg)
  • Acute treatment required proliferative retinopathy or maculopathy (macular oedema) according to physician's opinion
  • History of chronic pancreatitis or idiopathic acute pancreatitis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
413 participants (actual)

Study arms

  • Experimental
    IDegLira + metformin

    IDegLira was injected subcutaneously once daily for 26 weeks.

    Drug: insulin degludec/liraglutide

  • Experimental
    IDeg + metformin

    IDeg was injected subcutaneously once daily for 26 weeks.

    Drug: insulin degludec

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.

  • IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin)

    Observed mean change from baseline in HbA1c after 26 Weeks of treatment.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change in Body Weight

    Observed mean change from baseline in body weight after 26 Weeks of treatment.

    Time frame: Week 0, week 26

08

Results

Posted Jan 20, 2017

Participant flow

The trial was conducted at 75 sites in 7 countries: Bulgaria (6), Switzerland (2), Denmark (3), Hungary (3), India (6), Slovenia (3), and the United States (52).

Participant flow — Overall Study
MilestoneIDegLiraIDeg
Started207206
Exposed207206
Completed175171
Not completed3235
Withdrew: Adverse event13
Withdrew: Lack of efficacy12
Withdrew: Protocol violation02
Withdrew: Withdrawal criteria1315
Withdrew: Site closure87
Withdrew: Unclassified96

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Haemoglobin)

Observed mean change from baseline in HbA1c after 26 Weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
percentage of glycosylated haemoglobinIDegLiraIDeg
Change From Baseline in HbA1c (Glycosylated Haemoglobin)-1.90 ± 1.09-0.89 ± 1.18
Statistical analysis
  • IDegLira vs IDeg · ANCOVA · p = <0.0001 · Treatment contrast: -1.05 · 95% CI -1.25 to -0.84ANCOVA model with treatment, country and previous antidiabetic treatment as fixed effects and baseline HbA1c value as covariate
SecondaryChange in Body Weight

Observed mean change from baseline in body weight after 26 Weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · kg
Change in Body Weight
kgIDegLiraIDeg
Change in Body Weight-2.7 ± 3.70.0 ± 3.4

Adverse events

Collected over Adverse events were captured from the time of consent untill 26 weeks of treatment, and were followed-up for 7 days after the final visit (upto overall 27 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegLira—7/199 (3.5%)45/199 (22.6%)
IDeg—11/199 (5.5%)29/199 (14.6%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventIDegLiraIDeg
Acute myocardial infarctionCardiac disorders1/1991/199
Atrial fibrillationCardiac disorders1/1990/199
Ventricular fibrillationCardiac disorders1/1990/199
Ventricular tachycardiaCardiac disorders1/1990/199
Cholecystitis acuteHepatobiliary disorders1/1990/199
PneumoniaInfections and infestations1/1991/199
Vestibular neuronitisInfections and infestations1/1990/199
Acetabulum fractureInjury, poisoning and procedural complications0/1991/199
Foot fractureInjury, poisoning and procedural complications0/1991/199
Humerus fractureInjury, poisoning and procedural complications0/1991/199
Most frequent other events
Most frequent other events
EventIDegLiraIDeg
DiarrhoeaGastrointestinal disorders13/1997/199
NauseaGastrointestinal disorders13/1997/199
NasopharyngitisInfections and infestations5/19912/199
Lipase increasedInvestigations12/1997/199
HeadacheNervous system disorders12/1994/199

Baseline characteristics

Full analysis set (FAS) included all randomised subjects except 15 subjects (8 in IDegLira arm and 7 in IDeg arm) that were excluded due to site closure.

Age, Continuous
Age, Continuous(years)IDegLiraIDegTotal
Mean56.8 ± 8.957.5 ± 10.557.2 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)IDegLiraIDegTotal
Female8793180
Male112106218
HbA1c (glycosylated haemoglobin)
HbA1c (glycosylated haemoglobin)(percentage of glycosylated haemoglobin)IDegLiraIDegTotal
Mean8.7 ± 0.78.8 ± 0.78.8 ± 0.7
Body Weight
Body Weight(kg)IDegLiraIDegTotal
Mean95.4 ± 19.493.5 ± 20.094.5 ± 19.7
09

Study locations

86 sites
  • Novo Nordisk Investigational Site
    Huntsville, Alabama 35801, United States
  • Novo Nordisk Investigational Site
    Vestavia Hills, Alabama 35209, United States
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    Tustin, California 92780, United States
  • Novo Nordisk Investigational Site
    Ventura, California 93003, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80910, United States
  • Novo Nordisk Investigational Site
    Waterbury, Connecticut 06708, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32934, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33156, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Arlington Heights, Illinois 60004-2315, United States
  • Novo Nordisk Investigational Site
    Avon, Illinois 46123, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Crystal Lake, Illinois 60012, United States
  • Novo Nordisk Investigational Site
    Gurnee, Illinois 60031, United States
  • Novo Nordisk Investigational Site
    Greenfield, Indiana 46140, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46254, United States
  • Novo Nordisk Investigational Site
    Muncie, Indiana 47304, United States
  • Novo Nordisk Investigational Site
    New Albany, Indiana 47150, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70002, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70006-2930, United States
  • Novo Nordisk Investigational Site
    Slidell, Louisiana 70461-4231, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Methuen, Massachusetts 01844, United States
  • Novo Nordisk Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • Novo Nordisk Investigational Site
    Waltham, Massachusetts 02453, United States
  • Novo Nordisk Investigational Site
    Southfield, Michigan 48034-7661, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    Saint Charles, Missouri 63303, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Toms River, New Jersey 08755-8050, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Smithtown, New York 11787, United States
  • Novo Nordisk Investigational Site
    Asheboro, North Carolina 27203, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27517, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27408, United States
  • Novo Nordisk Investigational Site
    Hickory, North Carolina 28602, United States
  • Novo Nordisk Investigational Site
    Statesville, North Carolina 28625, United States
  • Novo Nordisk Investigational Site
    Beaver, Pennsylvania 15009, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19152, United States
  • Novo Nordisk Investigational Site
    Greer, South Carolina 29651, United States
  • Novo Nordisk Investigational Site
    Simpsonville, South Carolina 29681, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37203, United States
  • Novo Nordisk Investigational Site
    Arlington, Texas 76014, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75251, United States
  • Novo Nordisk Investigational Site
    Hurst, Texas 76054, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78215, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78224, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78229, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Salt Lake City, Utah 84107, United States
  • Novo Nordisk Investigational Site
    Burgas, 8000, Bulgaria
  • Novo Nordisk Investigational Site
    Haskovo, 6300, Bulgaria
  • Novo Nordisk Investigational Site
    Lukovit, 5770, Bulgaria
  • Novo Nordisk Investigational Site
    Plovdiv, 4001, Bulgaria
  • Novo Nordisk Investigational Site
    Ruse, 7000, Bulgaria
  • Novo Nordisk Investigational Site
    Sofia, 1712, Bulgaria
  • Novo Nordisk Investigational Site
    Gentofte, 2820, Denmark
  • Novo Nordisk Investigational Site
    Hellerup, 2900, Denmark
  • Novo Nordisk Investigational Site
    Århus C, 8000, Denmark
  • Novo Nordisk Investigational Site
    Budapest, 1125, Hungary
  • Novo Nordisk Investigational Site
    Debrecen, 4043, Hungary
  • Novo Nordisk Investigational Site
    Eger, H-3300, Hungary
  • Novo Nordisk Investigational Site
    Szombathely, H-9700, Hungary
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400008, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400053, India
  • Novo Nordisk Investigational Site
    Pune, Maharashtra 411001., India
  • Novo Nordisk Investigational Site
    Chennai, Tamil Nadu 600086, India
  • Novo Nordisk Investigational Site
    Kolkata, West Bengal 700064, India
  • Novo Nordisk Investigational Site
    Dhantoli, Nagpur, 440012, India
  • Novo Nordisk Investigational Site
    Koper, SI-6000, Slovenia
  • Novo Nordisk Investigational Site
    Ljubljana, 1525, Slovenia
  • Novo Nordisk Investigational Site
    Novo mesto, 8000, Slovenia
  • Novo Nordisk Investigational Site
    Basel, 4031, Switzerland
  • Novo Nordisk Investigational Site
    Bern, 3010, Switzerland
  • Novo Nordisk Investigational Site
    Interlaken-Unterseen, 3800, Switzerland
  • Novo Nordisk Investigational Site
    Lausanne, 1011, Switzerland
  • Novo Nordisk Investigational Site
    Luzern 16, 6000, Switzerland
  • Novo Nordisk Investigational Site
    St. Gallen, 9007, Switzerland
10

References and documents

Publications

  • Khunti K, Mohan V, Jain SM, Boesgaard TW, Begtrup K, Sethi B. Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program. Diabetes Ther. 2017 Jun;8(3):673-682. doi: 10.1007/s13300-017-0252-9. Epub 2017 Mar 22. PubMed 28332144 ↗
  • Ericsson A, Lundqvist A. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden. Appl Health Econ Health Policy. 2017 Apr;15(2):237-248. doi: 10.1007/s40258-016-0301-y. PubMed 28063135 ↗
  • Buse JB, Vilsboll T, Thurman J, Blevins TC, Langbakke IH, Bottcher SG, Rodbard HW; NN9068-3912 (DUAL-II) Trial Investigators. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014 Nov;37(11):2926-33. doi: 10.2337/dc14-0785. Epub 2014 Aug 11. PubMed 25114296 ↗
  • Vilsboll T, Vora J, Jarlov H, Kvist K, Blonde L. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clin Drug Investig. 2016 Apr;36(4):293-303. doi: 10.1007/s40261-016-0376-0. PubMed 26894800 ↗
  • King AB, Philis-Tsimikas A, Kilpatrick ES, Langbakke IH, Begtrup K, Vilsboll T. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. Diabetes Technol Ther. 2017 Apr;19(4):255-264. doi: 10.1089/dia.2016.0405. Epub 2017 Mar 10. PubMed 28282219 ↗
  • Lingvay I, Handelsman Y, Linjawi S, Vilsboll T, Halladin N, Ranc K, Liebl A. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb;25(2):144-155. doi: 10.4158/EP-2018-0284. Epub 2018 Nov 1. PubMed 30383495 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Oct 2012, 10 months.

Results were first posted in Jan 2017, 4 years 3 months after primary completion. A results delay was requested in Dec 2012.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2011
First posted
Jul 12, 2011
StartActual
Nov 28, 2011
Primary completionActual
Oct 1, 2012
CompletionActual
Oct 4, 2012
Results delay requested
Dec 19, 2012
Results first posted
Jan 20, 2017
Last update
Jan 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01392573
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 12, 2011
Start date
Nov 28, 2011
Primary completion
Oct 1, 2012
Completion
Oct 4, 2012
Results posted
Jan 20, 2017
Last update
Jan 3, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion